Figure 3.

Evaluation of progression-free survival (PFS) of patients and redistribution of sensitivity to platinum according to the histological type. (A) Evaluation of PFS of patients with clear cell/mucinous adenocarcinoma who relapsed after 12 months (n=7, red line). The PFS was significantly shorter compared to that of patients with serous/endometrioid adenocarcinoma who relapsed after 12 months (n=34, blue line). (B) The PFS of patients with clear cell/mucinous adenocarcinoma who relapsed after 12 months (n=7, red line) was similar to that of patients with serous/endometrioid adenocarcinoma who relapsed between 6 and 12 months (n=17, blue line). (C) Comparison of PFS between patients with clear cell/mucinous adenocarcinoma (n=6, red line) and those with serous/endometrioid adenocarcinoma (n=17, blue line) who relapsed between 6 and 12 months.